March 21, 2023
VIA EDGAR |
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Tim Buchmiller
| Re: | ADC Therapeutics SA Registration Statement on Form F-3 Registration No. 333-270570 |
In accordance with Rule 461 under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form F-3 (File No. 333-270570) (the “Registration Statement”) of ADC Therapeutics SA. We respectfully request that the Registration Statement be declared effective as of 4:30 p.m., Eastern time, on March 24, 2023, or as soon as practicable thereafter.
Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Davis Polk & Wardwell LLP, by calling David Li at (212) 450-3861.
Thank you for your assistance in this matter.
Sincerely,
ADC Therapeutics SA | |||
| By: | /s/ Peter J. Graham | ||
| Name: | Peter J. Graham | ||
| Title: | Chief Legal Officer | ||